These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 33585529)

  • 21. Clinical characteristics and outcomes of critically ill COVID-19 patients in Tokyo: a single-center observational study from the first wave.
    Banno A; Hifumi T; Okamoto H; Masaki M; Seki K; Isokawa S; Otani N; Hayashi K; Ishimatsu S
    BMC Infect Dis; 2021 Feb; 21(1):163. PubMed ID: 33563218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
    Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
    Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion.
    Farhat RM; Mousa MA; Daas EJ; Glassberg MK
    Front Med (Lausanne); 2020; 7():435. PubMed ID: 32850916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Convalescent Plasma Therapy in Four Critically Ill Pediatric Patients With Coronavirus Disease 2019: A Case Series.
    Schwartz SP; Thompson P; Smith M; Lercher DM; Rimland CA; Bartelt L; Park YA; Weiss S; Markmann AJ; Raut R; Premkumar L; Kuruc J; Willis Z
    Crit Care Explor; 2020 Oct; 2(10):e0237. PubMed ID: 33063037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates.
    Verma HK; Farran B; Bhaskar LVKS
    Antib Ther; 2020 Apr; 3(2):115-125. PubMed ID: 33912791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas.
    Salazar E; Perez KK; Ashraf M; Chen J; Castillo B; Christensen PA; Eubank T; Bernard DW; Eagar TN; Long SW; Subedi S; Olsen RJ; Leveque C; Schwartz MR; Dey M; Chavez-East C; Rogers J; Shehabeldin A; Joseph D; Williams G; Thomas K; Masud F; Talley C; Dlouhy KG; Lopez BV; Hampton C; Lavinder J; Gollihar JD; Maranhao AC; Ippolito GC; Saavedra MO; Cantu CC; Yerramilli P; Pruitt L; Musser JM
    medRxiv; 2020 May; ():. PubMed ID: 32511574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience.
    Nusshag C; Morath C; Speer C; Kaelble F; Zeier M; Boxberger M; Schulze-Schleithoff E; Fiedler MO; Weigand MA; Merle U
    Crit Care Explor; 2021 Aug; 3(8):e0517. PubMed ID: 34476404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential predictors of outcomes among hospitalized COVID-19 patients treated with convalescent plasma: a single-center study.
    Chilimuri S; Zahid M; Mantri N; Sun H; Saleh M; Ashraf S; Gongati S; Adrish M
    J Community Hosp Intern Med Perspect; 2021 Jun; 11(4):464-469. PubMed ID: 34211649
    [No Abstract]   [Full Text] [Related]  

  • 30. The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma.
    Ma T; Wiggins CC; Kornatowski BM; Hailat RS; Clayburn AC; Guo W; Johnson PW; Senefeld JW; Klassen SA; Baker SE; Bruno KA; Fairweather D; Wright RS; Carter RE; Li C; Joyner MJ; Paneth N
    medRxiv; 2021 Jan; ():. PubMed ID: 33501470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of time and titer in convalescent plasma therapy for COVID-19.
    de Candia P; Prattichizzo F; Garavelli S; La Grotta R; De Rosa A; Pontarelli A; Parrella R; Ceriello A; Matarese G
    iScience; 2021 Aug; 24(8):102898. PubMed ID: 34316549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Informative Censoring-A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data.
    Lin HM; Liu STH; Levin MA; Williamson J; Bouvier NM; Aberg JA; Reich D; Egorova N
    Life (Basel); 2023 Jan; 13(1):. PubMed ID: 36676159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial.
    Franchini M; Glingani C; Morandi M; Corghi G; Cerzosimo S; Beduzzi G; Storti A; Di Stasi V; Rastrelli G; Vignozzi L; Mengoli C; Garuti M; Beccaria M; Inglese F; Caruso B; Petilino RA; Amato M; Nicchio M; Pagani M; Bellani A; Castelli G; Casari S; De Donno G
    Mayo Clin Proc Innov Qual Outcomes; 2021 Apr; 5(2):403-412. PubMed ID: 33585799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients.
    Klapholz M; Pentakota SR; Zertuche JP; McKenna M; Roque W; Forsberg M; Packer J; Lal DS; Dever L
    Open Forum Infect Dis; 2021 Feb; 8(2):ofab001. PubMed ID: 33604400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study.
    Tworek A; Jaroń K; Uszyńska-Kałuża B; Rydzewski A; Gil R; Deptała A; Franek E; Wójtowicz R; Życińska K; Walecka I; Cicha M; Wierzba W; Zaczyński A; Król ZJ; Rydzewska G
    Int J Infect Dis; 2021 Apr; 105():209-215. PubMed ID: 33607305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 convalescent plasma: Interim recommendations from the AABB.
    Cohn CS; Estcourt L; Grossman BJ; Pagano MB; Allen ES; Bloch EM; Casadevall A; Devine DV; Dunbar NM; Foroutan F; Gniadek TJ; Goel R; Gorlin J; Joyner MJ; Metcalf RA; Raval JS; Rice TW; Shaz BH; Vassallo RR; Winters JL; Beaudoin G; Tobian AAR
    Transfusion; 2021 Apr; 61(4):1313-1323. PubMed ID: 33586160
    [No Abstract]   [Full Text] [Related]  

  • 37. Effectiveness of convalescent plasma in Indian patients with COVID-19.
    Budhiraja S; Dewan A; Aggarwal R; Singh O; Juneja D; Pathak S; Singh YP; Gupta A; Rai R; Indrayan A; Jha V; Naithani R
    Blood Cells Mol Dis; 2021 May; 88():102548. PubMed ID: 33621948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman.
    Al Harthi S; Osali MA; Kindi NA; Kharusi ZA; Qasabi SA; Hinai MA; Ghafri TA
    Health Serv Res Manag Epidemiol; 2021; 8():2333392820986639. PubMed ID: 33623809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial.
    Jamaati H; Hashemian SM; Farzanegan B; Malekmohammad M; Tabarsi P; Marjani M; Moniri A; Abtahian Z; Haseli S; Mortaz E; Dastan A; Mohamadnia A; Vahedi A; Monjazebi F; Yassari F; Fadaeizadeh L; Saffaei A; Dastan F
    Eur J Pharmacol; 2021 Apr; 897():173947. PubMed ID: 33607104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia.
    Pascual Pareja JF; García-Caballero R; Soler Rangel L; Vázquez-Ronda MA; Roa Franco S; Navarro Jiménez G; Moreno Palanco MA; González-Ruano P; López-Menchaca R; Ruíz-Seco P; Pagán Muñoz B; Gómez Gómez A; Pérez-Monte B; Fuerte Martínez R; Valle López JL; Muñoz Blanco A; Rábago Lorite I; Martínez Martín P; Serralta San Martín G; Gómez-Cerezo JF;
    Med Clin (Engl Ed); 2021 Mar; 156(5):221-228. PubMed ID: 33585689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.